SK284505B6 - Použitie kombinácie diolu a alfa-hydroxykyseliny vo vehikule na prípravu liečiva určeného na topickú liečbu hyperkeratóznych kožných ochorení - Google Patents

Použitie kombinácie diolu a alfa-hydroxykyseliny vo vehikule na prípravu liečiva určeného na topickú liečbu hyperkeratóznych kožných ochorení Download PDF

Info

Publication number: SK284505B6
Authority: SK; Slovakia
Prior art keywords: alpha; vehicle; diol; skin diseases; hydroxy acid
Prior art date: 1997-11-25

Application number

SK743-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK7432000A3 (en

Inventor

Agneta Ganemo

Original Assignee

Yamanouchi Europe B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-25

Filing date

1998-11-25

Publication date

2005-05-05

1998-11-25 Application filed by Yamanouchi Europe B.V. filed Critical Yamanouchi Europe B.V.

2001-05-10 Publication of SK7432000A3 publication Critical patent/SK7432000A3/sk

2005-05-05 Publication of SK284505B6 publication Critical patent/SK284505B6/sk

Links

150000001280 alpha hydroxy acids Chemical class 0.000 title claims abstract description 16
229940061720 alpha hydroxy acid Drugs 0.000 title claims abstract description 15
208000017520 skin disease Diseases 0.000 title claims abstract description 12
230000000699 topical effect Effects 0.000 title claims abstract description 11
150000002009 diols Chemical class 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title claims abstract description 8
239000003814 drug Substances 0.000 title claims abstract description 6
230000001329 hyperkeratotic effect Effects 0.000 title abstract description 7
239000000126 substance Substances 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 39
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
238000009472 formulation Methods 0.000 description 16
239000006071 cream Substances 0.000 description 12
230000000694 effects Effects 0.000 description 12
239000003981 vehicle Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000004310 lactic acid Substances 0.000 description 9
235000014655 lactic acid Nutrition 0.000 description 9
239000012188 paraffin wax Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 8
206010020649 Hyperkeratosis Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
206010021198 ichthyosis Diseases 0.000 description 7
239000002105 nanoparticle Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 5
-1 for example Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 4
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
208000001913 Lamellar ichthyosis Diseases 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000007794 irritation Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000036572 transepidermal water loss Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
206010040880 Skin irritation Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229960005339 acitretin Drugs 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
229940051250 hexylene glycol Drugs 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
230000008591 skin barrier function Effects 0.000 description 2
230000036556 skin irritation Effects 0.000 description 2
231100000475 skin irritation Toxicity 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000003860 topical agent Substances 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
206010021197 Ichthyoses Diseases 0.000 description 1
229940124091 Keratolytic Drugs 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001277 beta hydroxy acids Chemical class 0.000 description 1
229950009789 cetomacrogol 1000 Drugs 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000009223 counseling Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940086555 cyclomethicone Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
230000001530 keratinolytic effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000001185 psoriatic effect Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
230000036620 skin dryness Effects 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002047 solid lipid nanoparticle Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000009121 systemic therapy Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK743-2000A 1997-11-25 1998-11-25 Použitie kombinácie diolu a alfa-hydroxykyseliny vo vehikule na prípravu liečiva určeného na topickú liečbu hyperkeratóznych kožných ochorení SK284505B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97203681		1997-11-25
PCT/EP1998/007759 WO1999026617A1 (en)	1997-11-25	1998-11-25	Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases

Publications (2)

Publication Number	Publication Date
SK7432000A3 SK7432000A3 (en)	2001-05-10
SK284505B6 true SK284505B6 (sk)	2005-05-05

Family

ID=8228970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK743-2000A SK284505B6 (sk)	1997-11-25	1998-11-25	Použitie kombinácie diolu a alfa-hydroxykyseliny vo vehikule na prípravu liečiva určeného na topickú liečbu hyperkeratóznych kožných ochorení

Country Status (21)

Country	Link
US (1)	US6399082B1 (cs)
EP (1)	EP1032378B1 (cs)
CN (1)	CN1140266C (cs)
AT (1)	ATE213939T1 (cs)
AU (1)	AU754420B2 (cs)
BG (1)	BG64743B1 (cs)
BR (1)	BR9815016A (cs)
CA (1)	CA2310049C (cs)
CZ (1)	CZ290165B6 (cs)
DE (1)	DE69804130T2 (cs)
DK (1)	DK1032378T3 (cs)
ES (1)	ES2174533T3 (cs)
HU (1)	HU226065B1 (cs)
IS (1)	IS2147B (cs)
NO (1)	NO320100B1 (cs)
NZ (1)	NZ504458A (cs)
PL (1)	PL190023B1 (cs)
PT (1)	PT1032378E (cs)
SK (1)	SK284505B6 (cs)
TR (1)	TR200001486T2 (cs)
WO (1)	WO1999026617A1 (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5778367A (en) *	1995-12-14	1998-07-07	Network Engineering Software, Inc.	Automated on-line information service and directory, particularly for the world wide web
US6841539B1 (en) *	1998-05-21	2005-01-11	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6410036B1 (en)	2000-05-04	2002-06-25	E-L Management Corp.	Eutectic mixtures in cosmetic compositions
AU2002314847A1 (en)	2001-05-31	2002-12-09	Upsher-Smith Laboratories, Inc.	Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
US20060257337A1 (en) *	2005-04-28	2006-11-16	David Sherris	Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
USRE46558E1 (en)	2005-04-28	2017-09-26	Paloma Pharmaceuticals, Inc.	Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20070189989A1 (en) *	2006-02-16	2007-08-16	Cantwell Maggie Y	Cosmetic compositions and methods of making and using the compositions
AU2007219981B2 (en)	2006-02-28	2013-11-07	Paloma Pharmaceuticals, Inc.	Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
WO2009120799A2 (en) *	2008-03-25	2009-10-01	Paloma Pharmaceuticals, Inc.	Methods of treating fibrotic disorders
ES2336995B1 (es)	2008-10-13	2011-02-09	Lipotec, S.A.	Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
EP2419087B1 (en) *	2009-04-13	2013-01-23	Sulur, Vanangamudi Subramaniam	A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
WO2010127411A1 (en) *	2009-05-08	2010-11-11	Allmedic Pty Ltd	Treatment of pain and/or inflammation and treatment and prevention of a skin or mucosal disease and/or condition
JP2013541590A (ja) *	2010-11-04	2013-11-14	４４２ヴェンチャーズ，エルエルシー	皮膚の病的状態を治療するための組成物及び方法
US9381187B2 (en)	2011-02-16	2016-07-05	Paloma Pharmaceuticals, Inc.	Radiation countermeasure agents
GB2540764A (en) *	2015-07-24	2017-02-01	Fontus Health Ltd	Topical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4021572A (en) *	1975-07-23	1977-05-03	Scott Eugene J Van	Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
SE462139B (sv) *	1986-02-04	1990-05-14	Sven Moberg	Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5525635A (en) *	1986-02-04	1996-06-11	Moberg; Sven	Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
AU658608B2 (en) *	1991-03-25	1995-04-27	Astellas Pharma Europe B.V.	Topical preparation containing a suspension of solid lipid particles
WO1994013257A1 (en) *	1992-12-16	1994-06-23	Creative Products Resource Associates, Ltd.	Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5407958A (en) *	1993-07-30	1995-04-18	Beauticontrol Cosmetics, Inc.	Therapeutic skin composition
AU7656894A (en) *	1993-09-15	1995-04-03	Unilever Plc	Skin care method and composition

1998
- 1998-11-25 PL PL98340679A patent/PL190023B1/pl unknown
- 1998-11-25 WO PCT/EP1998/007759 patent/WO1999026617A1/en not_active Ceased
- 1998-11-25 HU HU0100066A patent/HU226065B1/hu not_active IP Right Cessation
- 1998-11-25 SK SK743-2000A patent/SK284505B6/sk not_active IP Right Cessation
- 1998-11-25 CZ CZ20001920A patent/CZ290165B6/cs not_active IP Right Cessation
- 1998-11-25 US US09/554,330 patent/US6399082B1/en not_active Expired - Lifetime
- 1998-11-25 AU AU19659/99A patent/AU754420B2/en not_active Expired
- 1998-11-25 CA CA002310049A patent/CA2310049C/en not_active Expired - Lifetime
- 1998-11-25 PT PT98964471T patent/PT1032378E/pt unknown
- 1998-11-25 AT AT98964471T patent/ATE213939T1/de active
- 1998-11-25 EP EP98964471A patent/EP1032378B1/en not_active Expired - Lifetime
- 1998-11-25 NZ NZ504458A patent/NZ504458A/en not_active IP Right Cessation
- 1998-11-25 CN CNB988115557A patent/CN1140266C/zh not_active Expired - Lifetime
- 1998-11-25 DE DE69804130T patent/DE69804130T2/de not_active Expired - Lifetime
- 1998-11-25 BR BR9815016-2A patent/BR9815016A/pt not_active Application Discontinuation
- 1998-11-25 DK DK98964471T patent/DK1032378T3/da active
- 1998-11-25 ES ES98964471T patent/ES2174533T3/es not_active Expired - Lifetime
- 1998-11-25 TR TR2000/01486T patent/TR200001486T2/xx unknown
2000
- 2000-05-23 BG BG104470A patent/BG64743B1/bg unknown
- 2000-05-23 IS IS5505A patent/IS2147B/is unknown
- 2000-05-24 NO NO20002649A patent/NO320100B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1140266C (zh)	2004-03-03
ATE213939T1 (de)	2002-03-15
HUP0100066A2 (hu)	2001-08-28
AU754420B2 (en)	2002-11-14
CN1280495A (zh)	2001-01-17
CZ20001920A3 (cs)	2001-04-11
NO20002649D0 (no)	2000-05-24
EP1032378B1 (en)	2002-03-06
WO1999026617A1 (en)	1999-06-03
HU226065B1 (hu)	2008-04-28
ES2174533T3 (es)	2002-11-01
EP1032378A1 (en)	2000-09-06
AU1965999A (en)	1999-06-15
PL340679A1 (en)	2001-02-12
HK1034194A1 (en)	2001-10-19
PT1032378E (pt)	2002-07-31
BG64743B1 (bg)	2006-02-28
NZ504458A (en)	2002-03-01
NO20002649L (no)	2000-07-24
DE69804130D1 (de)	2002-04-11
BG104470A (en)	2001-03-30
DE69804130T2 (de)	2002-07-25
SK7432000A3 (en)	2001-05-10
TR200001486T2 (tr)	2001-07-23
BR9815016A (pt)	2000-10-03
CZ290165B6 (cs)	2002-06-12
HUP0100066A3 (en)	2006-07-28
US6399082B1 (en)	2002-06-04
CA2310049A1 (en)	1999-06-03
IS2147B (is)	2006-09-15
PL190023B1 (pl)	2005-10-31
CA2310049C (en)	2008-02-19
NO320100B1 (no)	2005-10-24
DK1032378T3 (da)	2002-04-15
IS5505A (is)	2000-05-23

Legal Events

Date

Code

Title

Description

2016-06-01

TE4A

Change of owner's address

Owner name: ASTELLAS PHARMA EUROPE B.V., BE LEIDEN, NL

Effective date: 20160511

2017-04-03

PC4A

Assignment and transfer of rights

Owner name: LEO PHARMA A/S, BALLERUP, DK

Free format text: FORMER OWNER: ASTELLAS PHARMA EUROPE B.V., BE LEIDEN, NL

Effective date: 20160523

2019-01-08

MK4A

Expiry of patent

Expiry date: 20181125

Publication	Publication Date	Title
US4839159A (en)	1989-06-13	Topical L-carnitine composition
JP2686365B2 (ja)	1997-12-08	陸生哺乳類の皮膚炎治療剤
Lodén	2003	Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders
US4760096A (en)	1988-07-26	Moisturizing skin preparation
CA1336762C (en)	1995-08-22	Method and composition for treating and preventing dry skin disorders
US5616332A (en)	1997-04-01	Cosmetic skin-renewal-stimulating composition with long-term irritation control
US4871752A (en)	1989-10-03	Use of aryloxycarboxylic acid derivatives against dermatological diseases
JP2001510487A (ja)	2001-07-31	遊離スフィンゴイド塩基及びセラミドの組合せを含む組成物並びにその使用
SK7432000A3 (en)	2001-05-10	Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
US5045559A (en)	1991-09-03	Treatment of skin disorders
US5508034A (en)	1996-04-16	Method and composition for treating and preventing dry skin disorders
US20160243011A1 (en)	2016-08-25	Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof
US20060127342A1 (en)	2006-06-15	Taurine-based compositions, therapeutic methods, and assays
WO1999026613A1 (en)	1999-06-03	Aminoguanidine compositions for treating skin proliferative diseases
EP0020532B1 (en)	1983-07-13	Lecithin-triethanolamine skin preparation
EP1080719A2 (en)	2001-03-07	Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids
JP2781982B2 (ja)	1998-07-30	皮膚外用剤
US20190060260A1 (en)	2019-02-28	N-bromotaurine solutions and emulsions against abnormal cells
MXPA00005078A (en)	2002-02-26	Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
JP2025019859A (ja)	2025-02-07	皮膚のバリア機能改善剤
CA2270561A1 (en)	1998-05-14	Synergistic gold-containing compositions
JP2017031133A (ja)	2017-02-09	フコキサンチンによるかゆみ抑制
HK1034194B (en)	2005-01-28	Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
IE54490B1 (en)	1989-10-25	Pharmaceutical composition containing an aliphatic amino sulphonic acid
JPH0328402B2 (cs)	1991-04-19